Back
47
50
Day Range
$62.63
$65.11
52-Week Range
$47.50
$82.22
Volume
1,809,170
50D / 200D Avg
$71.41
/
$66.89
Prev Close
$63.43
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (625 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 23.4 | 14.0 |
| P/B | 152.0 | 2.4 |
| ROE % | 153.6 | 11.4 |
| Net Margin % | 22.7 | 10.1 |
| Rev Growth 5Y % | 33.2 | 7.0 |
| D/E | 0.0 | 0.5 |
Key Takeaways
Revenue grew 33.23% annually over 5 years — strong growth
Earnings declined -28.64% over the past year
ROE of 153.59% indicates high profitability
Net margin of 22.69% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 644.59M in free cash flow
Growth
Revenue Growth (5Y)
33.23%
Revenue (1Y)37.55%
Earnings (1Y)-28.64%
FCF Growth (3Y)31.41%
Quality
Return on Equity
153.59%
ROIC1254.19%
Net Margin22.69%
Op. Margin58.45%
Safety
Debt / Equity
0.00
Current Ratio4.66
Interest Coverage45.03
Valuation
P/E Ratio
23.41
P/B Ratio151.98
EV/EBITDA8.92
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 37.55% | Revenue Growth (3Y) | 29.78% |
| Earnings Growth (1Y) | -28.64% | Earnings Growth (3Y) | 6.08% |
| Revenue Growth (5Y) | 33.23% | Earnings Growth (5Y) | -5.82% |
| Profitability | |||
| Revenue (TTM) | 1.40B | Net Income (TTM) | 316.89M |
| ROE | 153.59% | ROA | 12.55% |
| Gross Margin | 78.13% | Operating Margin | 58.45% |
| Net Margin | 22.69% | Free Cash Flow (TTM) | 644.59M |
| ROIC | 1254.19% | FCF Growth (3Y) | 31.41% |
| Safety | |||
| Debt / Equity | 0.00 | Current Ratio | 4.66 |
| Interest Coverage | 45.03 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 23.41 | P/B Ratio | 151.98 |
| P/S Ratio | 5.31 | PEG Ratio | -1.04 |
| EV/EBITDA | 8.92 | Dividend Yield | 0.00% |
| Market Cap | 7.42B | Enterprise Value | 7.28B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.40B | 1.02B | 829.25M | 660.12M | 443.31M |
| Net Income | 316.89M | 444.09M | 281.59M | 202.13M | 402.71M |
| EPS (Diluted) | 2.56 | 3.43 | 2.10 | 1.44 | 2.74 |
| Gross Profit | 1.09B | 855.91M | 636.89M | 520.81M | 361.90M |
| Operating Income | 816.29M | 551.48M | 337.57M | 267.53M | 275.90M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.53B | 2.06B | 1.73B | 1.84B | 1.10B |
| Total Liabilities | 2.48B | 1.70B | 1.65B | 1.67B | 907.48M |
| Shareholders' Equity | 48.81M | 363.82M | 83.81M | 169.80M | 196.95M |
| Total Debt | 0.0 | 1.51B | 1.50B | 1.51B | 876.67M |
| Cash & Equivalents | 133.82M | 115.85M | 118.37M | 234.20M | 118.72M |
| Current Assets | 825.21M | 1.09B | 746.42M | 739.01M | 926.29M |
| Current Liabilities | 177.09M | 139.10M | 112.49M | 130.79M | 117.15M |
Strategy Scores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#443 of 1007
Custom
Capital Light Compounder
#67 of 208
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026
Entered
Capital Light Compounder
Mar 24, 2026